Your browser doesn't support javascript.
loading
Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide.
Guarín Téllez, Natalia Elizabeth; Moreno Calderón, Jairo Alexander; Muñoz-Galindo, Ivan Mauricio; Augusto Díaz Rojas, Jorge; Arévalo Roa, Helbert Orlando.
Afiliação
  • Guarín Téllez NE; National Health Risk Management, EPS Salud Total, Bogotá D.C. Colombia.
  • Moreno Calderón JA; National Health Risk Management, EPS Salud Total, Bogotá D.C. Colombia.
  • Muñoz-Galindo IM; National Health Risk Management, EPS Salud Total, Bogotá D.C. Colombia. Electronic address: ivan.mg7@gmail.com.
  • Augusto Díaz Rojas J; Faculty of Science, Pharmacy Department, National University of Colombia, Bogotá D.C., Colombia.
  • Arévalo Roa HO; National Health Risk Management, EPS Salud Total, Bogotá D.C. Colombia.
Value Health Reg Issues ; 11: 1-8, 2016 Dec.
Article em En | MEDLINE | ID: mdl-27986193
BACKGROUND: In Colombia, HIV and AIDS constitute one of the major diseases of high cost to the health system, making necessary health risk management of patients with this disease through comprehensive health care programs with their respective evaluation of results. OBJECTIVE: To evaluate the relative cost-effectiveness of a care program for patients with HIV/AIDS affiliated to a health insurer in Colombia, comparing their results in three Health care provider (HCP). METHODS: The study population corresponded to a cohort of patients older than 18 years with HIV/AIDS and affiliated to a health insurer in Colombia during 2011 and 2012. A cost-effectiveness and cost-utility analysis of a health care program for this population was performed on the basis of a Markov model, in which quality-adjusted life-years (QALYs) and life-years gained were assessed. This analysis was conducted from the insurer perspective. The time horizon was life expectancy. A discount rate of 3% was applied. RESULTS: Drugs accounted for 80.54% of care costs. The average annual cost of patients in health state 5 was 3 times higher than that of patients in state 1. HCP A compared with HCP B generated an additional 1.53 QALYs, with a rate of incremental cost-effectiveness of $2400 per QALY gained. HCP C showed a dominated behavior. The variables that most influence the uncertainty were the cost of HCP A in health state 5 (55.52%) and the cost of HCP B in state 3 (27.51%). CONCLUSIONS: HCP A is a very cost-effective option considering a threshold of 1 time the per-capita gross domestic product.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome da Imunodeficiência Adquirida / Custos de Cuidados de Saúde / Seguradoras Tipo de estudo: Evaluation_studies / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Humans País/Região como assunto: America do sul / Colombia Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2016 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome da Imunodeficiência Adquirida / Custos de Cuidados de Saúde / Seguradoras Tipo de estudo: Evaluation_studies / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Humans País/Região como assunto: America do sul / Colombia Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2016 Tipo de documento: Article País de publicação: Estados Unidos